These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25750072)

  • 81. The maraviroc expanded access program - safety and efficacy data from an open-label study.
    Lazzarin A; Reynes J; Molina JM; Valluri S; Mukwaya G; Heera J; Craig C; van der Ryst E; Sierra-Madero JG
    HIV Clin Trials; 2015; 16(1):10-21. PubMed ID: 25777185
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Prevalence of intermediate-stage age-related macular degeneration in patients with acquired immunodeficiency syndrome.
    Jabs DA; Van Natta ML; Sezgin E; Pak JW; Danis R;
    Am J Ophthalmol; 2015 Jun; 159(6):1115-1122.e1. PubMed ID: 25769246
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Prevalence of HIV and hepatitis B virus co-infection in sub-Saharan Africa and the potential impact and program feasibility of hepatitis B surface antigen screening in resource-limited settings.
    Stabinski L; OʼConnor S; Barnhart M; Kahn RJ; Hamm TE
    J Acquir Immune Defic Syndr; 2015 Apr; 68 Suppl 3(Suppl 3):S274-85. PubMed ID: 25768867
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Primate immune responses to HIV-1 Env formulated in the saponin-based adjuvant AbISCO-100 in the presence or absence of TLR9 co-stimulation.
    Martinez P; Sundling C; O'Dell S; Mascola JR; Wyatt RT; Karlsson Hedestam GB
    Sci Rep; 2015 Mar; 5():8925. PubMed ID: 25762407
    [TBL] [Abstract][Full Text] [Related]  

  • 85. History of passive antibody administration for prevention and treatment of infectious diseases.
    Graham BS; Ambrosino DM
    Curr Opin HIV AIDS; 2015 May; 10(3):129-34. PubMed ID: 25760933
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Multipurpose prevention technologies: the future of HIV and STI protection.
    Fernández-Romero JA; Deal C; Herold BC; Schiller J; Patton D; Zydowsky T; Romano J; Petro CD; Narasimhan M
    Trends Microbiol; 2015 Jul; 23(7):429-436. PubMed ID: 25759332
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Prevalence and factors associated with late HIV diagnosis.
    Dai SY; Liu JJ; Fan YG; Shan GS; Zhang HB; Li MQ; Ye DQ
    J Med Virol; 2015 Jun; 87(6):970-7. PubMed ID: 25758129
    [TBL] [Abstract][Full Text] [Related]  

  • 88. 'I was thinking too much': experiences of HIV-positive adults with common mental disorders and poor adherence to antiretroviral therapy in Zimbabwe.
    Kidia K; Machando D; Bere T; Macpherson K; Nyamayaro P; Potter L; Makadzange T; Munjoma R; Marufu M; Araya R; Safren S; O'Cleirigh C; Chibanda D; Abas M
    Trop Med Int Health; 2015 Jul; 20(7):903-13. PubMed ID: 25754063
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Recent developments in clinical trial designs for HIV vaccine research.
    Richert L; Lhomme E; Fagard C; Lévy Y; Chêne G; Thiébaut R
    Hum Vaccin Immunother; 2015; 11(4):1022-9. PubMed ID: 25751670
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The relationship of CSF and plasma cytokine levels in HIV infected patients with neurocognitive impairment.
    Yuan L; Liu A; Qiao L; Sheng B; Xu M; Li W; Chen D
    Biomed Res Int; 2015; 2015():506872. PubMed ID: 25821806
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials.
    Ford N; Shubber Z; Pozniak A; Vitoria M; Doherty M; Kirby C; Calmy A
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):422-9. PubMed ID: 25850607
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Repeated HIV Voluntary Counseling and Testing Increased Risk Behaviors Among Men Who Have Sex with Men in China: A Prospective Cohort Study.
    Lau JT; Li D; Wang Z; Lai CH
    AIDS Behav; 2015 Nov; 19(11):1966-77. PubMed ID: 25863465
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Antiretroviral Drug Use and HIV Drug Resistance Among HIV-Infected Black Men Who Have Sex With Men: HIV Prevention Trials Network 061.
    Chen I; Connor MB; Clarke W; Marzinke MA; Cummings V; Breaud A; Fogel JM; Laeyendecker O; Fields SD; Donnell D; Griffith S; Scott HM; Shoptaw S; del Rio C; Magnus M; Mannheimer S; Wheeler DP; Mayer KH; Koblin BA; Eshleman SH
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):446-52. PubMed ID: 25861015
    [TBL] [Abstract][Full Text] [Related]  

  • 94. CD41 T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa.
    Geng EH; Neilands TB; Thièbaut R; Bwana MB; Nash D; Moore RD; Wood R; Zannou DM; Althoff KN; Lim PL; Nachega JB; Easterbrook PJ; Kambugu A; Little F; Nakigozi G; Nakanjako D; Kiggundu V; Ki Li PC; Bangsberg DR; Fox MP; Prozesky H; Hunt PW; Davies MA; Reynolds SJ; Egger M; Yiannoutsos CT; Vittinghoff EV; Deeks SG; Martin JN
    Int J Epidemiol; 2015 Feb; 44(1):251-63. PubMed ID: 25859596
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Reductions in virological failure and drug resistance in Chinese antiretroviral-treated patients due to lamivudine-based regimens, 2003-12.
    Xing H; Ruan Y; Hsi JH; Kan W; Liao L; Leng X; Wang J; He C; Shao Y;
    J Antimicrob Chemother; 2015 Jul; 70(7):2097-103. PubMed ID: 25855758
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Time estimation and production in HIV-associated neurocognitive disorders (HAND).
    Doyle KL; Morgan EE; Weber E; Woods SP;
    J Int Neuropsychol Soc; 2015 Feb; 21(2):175-81. PubMed ID: 25854272
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Peripheral blood mononuclear cells HIV DNA levels impact intermittently on neurocognition.
    Cysique LA; Hey-Cunningham WJ; Dermody N; Chan P; Brew BJ; Koelsch KK
    PLoS One; 2015; 10(4):e0120488. PubMed ID: 25853424
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial.
    Dawson L; Garner S; Anude C; Ndebele P; Karuna S; Holt R; Broder G; Handibode J; Hammer SM; Sobieszczyk ME;
    Clin Trials; 2015 Aug; 12(4):394-402. PubMed ID: 25851992
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Implementation and Operational Research: Effects of CD4 Monitoring Frequency on Clinical End Points in Clinically Stable HIV-Infected Patients With Viral Suppression.
    Ahn JY; Boettiger D; Law M; Kumarasamy N; Yunihastuti E; Chaiwarith R; Lee MP; Sim BL; Oka S; Wong W; Kamarulzaman A; Kantipong P; Phanuphak P; Ng OT; Kiertiburanakul S; Zhang F; Pujari S; Ditangco R; Ratanasuwan W; Merati TP; Saphonn V; Sohn AH; Choi JY;
    J Acquir Immune Defic Syndr; 2015 Jul; 69(3):e85-92. PubMed ID: 25850606
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.